The document is a transcript of the Q4 FY26 post-results earnings call held on May 19, 2026, filed pursuant to SEBI Listing Regulations.
The event was an earnings conference call to discuss the company's financial and operational performance for the fourth quarter and full year ended March 31, 2026.
The call was held on May 19, 2026. A specific time was not mentioned in the transcript.
The stated purpose was to provide an overview of the annual performance and discuss key business drivers and initiatives.
The meeting was held after the earnings announcement, as it is described as a 'post-results' call.
Management participants included Dr. Sharvil Patel (Managing Director), Mr. Ganesh Nayak (Director), Mr. Tushar Shroff (CFO), Mr. Arvind Bothra (Head, Investor Relations), and Mr. Alok Garg (MD Office).
The transcript itself was made available as an attachment to the regulatory filing. No mention was made of a presentation deck, recording, or webcast being hosted elsewhere.
The transcript contains no explicit compliance language stating that no Unpublished Price Sensitive Information (UPSI) would be shared. The call included detailed financial results and forward-looking guidance, which had presumably already been disclosed.
Financial and Operational Highlights
The financial period discussed is Q4 FY26 and the full financial year FY26.
Full Year FY26 Performance: Consolidated revenue was ₹271.5 billion, up 17% YoY. EBITDA was ₹84.8 billion, up 20% YoY, with a margin of 31.2% (80 bps improvement). Net Profit (adjusted) was ₹54.6 billion, up 15% YoY. Net debt to EBITDA ratio was 0.5x.
Q4 FY26 Performance: Consolidated revenue was ₹75.9 billion, up 16% YoY and 11% QoQ. EBITDA was ₹25.6 billion, up 20% YoY and 41% QoQ, with a margin of 33.7% (110 bps YoY and 720 bps QoQ improvement). Net Profit (adjusted) was ₹15.9 billion, up 15% YoY and 43% QoQ.
Business Segment Performance (Q4 FY26):
North America (US & Canada): Revenue of ₹29.5 billion, up 5% QoQ. 3 ANDAs filed, 9 approvals received, 6 new products launched.
India Branded Formulations: Revenue growth of 15% YoY, outperforming the market. Launched biosimilars Nivolumab (Tishtha) and Aflibercept (Anyra), and semaglutide injection.
International Markets: Revenue of ₹8 billion, up 45% YoY.
Consumer Wellness: Revenue of ₹14.6 billion, up 61% YoY.
Medical Devices: Revenue of ₹3.3 billion.
FY27 Guidance: Management expects high-teens growth in consolidated revenue. North America business is expected to see single-digit growth. India business is expected to outperform the market by 200-400 basis points. EBITDA margin is expected to be in excess of 24%, factoring in an R&D expense of ~8% of revenue.
Strategic Updates: The company discussed its pivot towards specialty products, the proposed acquisition of Assertio Holdings (oncology supportive care), the integration of Comfort Click (consumer wellness), and expansion in the Medical Devices vertical (orthopedics, nephrology, cardiology).
R&D Updates: Desidustat received approval in China and orphan drug designation in the US for sickle cell disease. Zintrodiazine (anti-malarial) received DCGI approval for Phase-III trials in India. A Phase-III trial for a second biosimilar ADC was initiated in India.
Additional Notes Section
The regulatory filing included the full transcript of the earnings call as an attachment.
The announcement and transcript contained extensive financial data, including revenue, EBITDA, net profit, and segment-wise breakdowns for both Q4 and full-year FY26.
The document also contained forward-looking statements regarding FY27 guidance and strategic initiatives.
